PDS Biotechnology Corporation (PDSB)
NASDAQ: PDSB · Real-Time Price · USD
0.6852
+0.0123 (1.83%)
At close: Mar 9, 2026, 4:00 PM EDT
0.6851
-0.0001 (-0.01%)
After-hours: Mar 9, 2026, 4:00 PM EDT
PDS Biotechnology Employees
PDS Biotechnology had 24 employees as of December 31, 2024. The number of employees decreased by 1 or -4.00% compared to the previous year.
Employees
24
Change (1Y)
-1
Growth (1Y)
-4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,453,539
Market Cap
37.50M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 24 | -1 | -4.00% |
| Dec 31, 2023 | 25 | -1 | -3.85% |
| Dec 31, 2022 | 26 | 4 | 18.18% |
| Dec 31, 2021 | 22 | 7 | 46.67% |
| Dec 31, 2020 | 15 | 0 | - |
| Sep 30, 2020 | 13 | -1 | -7.14% |
| Jun 30, 2020 | 13 | -1 | -7.14% |
| Mar 31, 2020 | 16 | 6 | 60.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Celularity | 123 |
| Xilio Therapeutics | 64 |
| Atara Biotherapeutics | 38 |
| Jasper Therapeutics | 27 |
| Lisata Therapeutics | 26 |
| Actinium Pharmaceuticals | 25 |
| INmune Bio | 22 |
| Sensei Biotherapeutics | 15 |
PDSB News
- 17 days ago - PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval - GlobeNewsWire
- 5 weeks ago - PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - GlobeNewsWire
- 6 weeks ago - PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - GlobeNewsWire
- 2 months ago - PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint - GlobeNewsWire
- 3 months ago - PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - GlobeNewsWire
- 3 months ago - PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”) - GlobeNewsWire
- 4 months ago - PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update - GlobeNewsWire